pubmed-article:8811504 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C0001792 | lld:lifeskim |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C0023570 | lld:lifeskim |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C0376315 | lld:lifeskim |
pubmed-article:8811504 | lifeskim:mentions | umls-concept:C0143060 | lld:lifeskim |
pubmed-article:8811504 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:8811504 | pubmed:dateCreated | 1996-12-10 | lld:pubmed |
pubmed-article:8811504 | pubmed:abstractText | There is some evidence that Parkinson's disease (PD) seems to be a heterogenous and generalized brain disorder reflecting a degeneration of multiple neuronal networks, including somatostatinergic neurons. Somatostatin-like immunoreactivity (SLI) and its molecular forms, high molecular weight form (HMV-SST), somatostatin-14 (SST-14), somatostatin-25/28 (SST-25/28) and Des-ala-somatostatin (Des-ala-SST), as well as homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were estimated using HPLC and radioimmunoassay in the cerebrospinal fluid (CSF) of 35 aged parkinsonian patients with different stages of intellectual deterioration. The influence of L-dopa-treatment on these neurochemical parameters was evaluated. Without a correlation with dementia scores (p = 0.11), SLI was significantly reduced in PD in comparison to the control group (p < 0.05). The reduction was related to the progression of the disease. Correlations between SLI, HVA and 5-HIAA indicate a heterogenous brain disorder in PD with alterations of several transmitter systems and functions. Complex qualitative and quantitative changes in the molecular pattern of SLI are compatible with a dysregulated synthesis and/or posttranslational processing. L-dopa-treatment was associated with a significant increase of HVA (p < 0.05) and HMV-SST (p < 0.05) and a slight, but insignificant increase of SLI (p = 0.11). | lld:pubmed |
pubmed-article:8811504 | pubmed:language | eng | lld:pubmed |
pubmed-article:8811504 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8811504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8811504 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8811504 | pubmed:issn | 0300-9564 | lld:pubmed |
pubmed-article:8811504 | pubmed:author | pubmed-author:CramerHH | lld:pubmed |
pubmed-article:8811504 | pubmed:author | pubmed-author:SchimrigkKK | lld:pubmed |
pubmed-article:8811504 | pubmed:author | pubmed-author:StrubenFF | lld:pubmed |
pubmed-article:8811504 | pubmed:author | pubmed-author:HamannG FGF | lld:pubmed |
pubmed-article:8811504 | pubmed:author | pubmed-author:StrittmatterM... | lld:pubmed |
pubmed-article:8811504 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8811504 | pubmed:volume | 103 | lld:pubmed |
pubmed-article:8811504 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8811504 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8811504 | pubmed:pagination | 591-602 | lld:pubmed |
pubmed-article:8811504 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:meshHeading | pubmed-meshheading:8811504-... | lld:pubmed |
pubmed-article:8811504 | pubmed:year | 1996 | lld:pubmed |
pubmed-article:8811504 | pubmed:articleTitle | Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa. | lld:pubmed |
pubmed-article:8811504 | pubmed:affiliation | Department of Neurology, University of the Saarland, Homburg, Federal Republic of Germany. | lld:pubmed |
pubmed-article:8811504 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8811504 | lld:pubmed |